drugset / Trial / NCT00085189
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Phase 2
Completed
42 enrolled
University of Southern California
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells
Timeline
- Start
- 2004-05
- Primary completion
- 2007-09
- Completion
- 2007-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MAGE-3.1 | Protein / enzyme biologic | — | Subcutaneous |
| Subject | gp100 antigen | Peptide | — | Subcutaneous |
| Subject | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |
| Subject | multi-epitope melanoma peptide vaccine | Vaccine | — | Subcutaneous |
| Subject | tyrosinase peptide | Peptide | — | Subcutaneous |
| Background | agatolimod | Oligonucleotide (other) | — | Subcutaneous |